Large language models management of complex medication regimens: a case-based evaluation

Steven Xu shaochen.xu25@uga.edu Department of Computer Science, University of Georgia, Athens, GA

Amoreena Most, PharmD, BCCCP Amoreena.most@uga.edu University of Georgia College of Pharmacy, Augusta, GA, USA

Aaron Chase, PharmD AACHASE1@augusta.edu Wellstar MCG Health, Augusta, GA, USA

Tanner Hedrick, PharmD Tanner.hedrick@unchealth.unc.edu University of North Carolina Medical Center, Chapel Hill, NC, USA

Brian Murray, PharmD BRIAN.2.MURRAY@CUANSCHUTZ.EDU University of Colorado Skaggs School of Pharmacy, Aurora, CO, USA

Kelli Keats, PharmD kkeats@augusta.edu Wellstar MCG Health, Augusta, GA, USA

Susan Smith, MSCR Susan.Smith@uga.edu University of Georgia College of Pharmacy, Athens, GA, USA

Erin Barreto, PharmD Barreto.Erin@mayo.edu Mayo Clinic, Rochester, MN, USA

Tianming Liu, PhD tianmingliu@gmail.com UGA, Athens, GA, USA

Andrea Sikora, PharmD, MSCR, BCCCP, FCCM sikora@uga.edu University of Georgia College of Pharmacy, Department of Clinical and Administrative Pharmacy, Augusta, GA, USA

Conflicts of Interest: The authors have no conflicts of interest.

Funding: Funding: Funding through Agency of Healthcare Research and Quality was provided through R21HS028485 and R01HS029009.

Acknowledgements: Liana Ha, Garrett Brown

Abstract

Background: Large language models (LLMs) have shown capability in diagnosing complex medical cases and passing medical licensing exams, but to date, only limited evaluations have studied how LLMs interpret, analyze, and optimize complex medication regimens. The purpose of this evaluation was to test four LLMs ability to identify medication errors and appropriate medication interventions on complex patient cases from the intensive care unit (ICU).

Methods: A series of eight patient cases were developed by critical care pharmacists including history of present illness, laboratory values, vital signs, and medication regimens. Then, four LLMs (ChatGPT (GPT-3.5), ChatGPT (GPT-4), Claude2, and Llama2-7b) were prompted to develop a medication regimen for the patient. LLM generated medication regimens were then reviewed by a panel of seven critical care pharmacists to assess for presence of medication errors and clinical relevance. For each medication regimen recommended by the LLM, clinicians were asked to assess for if they would continue a medication, identify perceived medication errors in the medications recommended, identify the presence of life-threatening medication choices, and rank overall agreement on a 5-point Likert scale.

Results: The clinician panel rated to continue therapies recommended by the LLMs between 55.8-67.9% of the time. Clinicians perceived between 1.57-4.29 medication errors per recommended regimen, and life-threatening recommendations were present between 15.0-55.3% of the time. Level agreement was between 1.85-2.67 for the four LLMs.

Conclusions: LLMs demonstrated potential to serve as clinical decision support for the management of complex medication regimens with further domain specific training; however, caution should be used when employing LLMs for medication management given the present capabilities.

Keywords: Large language model; artificial intelligence; pharmacy; medication regimen complexity

Introduction

Large language models (LLMs) have demonstrated proficiency across a wide spectrum of natural language processing (NLP) tasks, including remarkable abilities for diagnosis of complex patient cases and passing medical licensing exams.^{1–3} In one evaluation, GPT-4 correctly diagnosed 57% of cases, thus outperforming 99.98% of simulated human readers based on online answers from the journal.^{1, 2} In another analysis, the LLM's top diagnosis was in agreement with 39% of the cases and in 64% of cases, the final diagnosis was in the LLM's differential list of diagnoses 64% of the time.^{2, 3}

However, these tasks have largely focused on structured diagnostic problems and have only limited evaluation in the domain of comprehensive medication management.⁴ Comprehensive medication management (CMM) refers to "the standard of care that ensures each patient's medications (whether they are prescription, nonprescription, alternative, traditional, vitamins, or nutritional supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given the comorbidities and other medications being taken, and able to be taken by the patient as intended"⁴ and is the cognitive service generally provided by clinical pharmacists.⁵ To date, LLMs have been tested for deprescribing benzodiazepines, identifying drug-herb interactions, and performance on a national pharmacist examination, showing early promise.^{5–7} Given that each year, it is estimated that 4 billion prescription medications are dispensed in the United States⁶ and there are approximately 1.8 million adverse drug events (ADEs) in hospitalized patients with estimates of 9,000 patients that die as a direct result of a medication error per year with an expected cost of \$40 billion in relation to medication errors,⁷ LLMs are an important tool towards making medication use safer.

Most LLMs were trained on a widely available corpus (e.g., the Internet), which creates the potential for problems in domains marked by highly technical language, as is a hallmark of medical and pharmacy domains.^{8,9} There have been calls for thoughtful evaluation prior to use in the healthcare setting.⁸ The purpose of this study was to compare performance of four LLMs (ChatGPT (GPT-3.5), ChatGPT (GPT-4), Claude2, and Llama2-7b) to appropriate analyze and optimize complex medication regimens for critically ill patients.

Methods

Data source. A total of eight patient cases were developed by critical care pharmacists. Patient cases were intended to reflect critically ill patients cared for in the intensive care unit (ICU) and incorporated a history of present illness, relevant laboratory and vital sign data, and present medication regimen. Additionally, critical care pharmacists provided a 'ground truth' medication regimen perceived to be the most appropriate with associated reasoning.

Study design. In designing the methodological framework for our study, the primary objective was to evaluate the capabilities of large language models (LLMs) in generating medication plans based on detailed patient medical records and scenarios. This involved a carefully structured prompting process, intended to elicit the most accurate and clinically relevant responses from the LLMs. Our study used a comparative analysis approach, testing across four advanced LLMs: GPT-3.5, GPT-4, LLaMa-2-70b, and Claude-2. The study encompassed a total of eight distinct patient cases, with one case serving as an initial example for single-shot training, and the subsequent seven cases utilized as actual test scenarios.

The approach employed a two-step prompting process designed to guide the LLMs through a structured evaluation of patient cases. This process was informed by the chain-of-thought method, which has been demonstrated to yield improved outcomes by facilitating a more indepth analysis by the LLMs.⁹ This approach is especially beneficial in complex decision-making tasks, such as medical treatment planning, where contextual understanding and synthesis of information are crucial.

Two-Step Prompting Process:

1. Initial Example Prompting: "Please review the case below and pay close attention to how the ground truth section at the end is structured." This step involved providing the LLMs with a comprehensive patient case, including detailed medical history, current treatment plans, and the ground truth medication plan. The LLMs were instructed to closely analyze the structure and formatting of the ground truth section, which outlined the updated medication plan. This initial example served as a form of single-shot training, aiming to familiarize the LLMs with the expected output format and clinical reasoning required for generating appropriate medication plans.

2. New Patient Scenario Prompting: "Now, I will give you a separate case, please review all the information given and based on it provide a new updated prescribed medication list exactly like how the ground truth section is structured and formatted in the example given before." Following the initial example, the LLMs were presented with new patient scenarios, each encompassing a unique set of medical records, current medication prescriptions, and clinical challenges. The LLMs were tasked with synthesizing this information to propose an updated medication plan, mirroring the structure and format of the ground truth example provided earlier.

A clinician panel was then asked to provide comprehensive medication management in reviewing the medication regimen generated by each of the four LLMs for the 7 patient cases. Each individual was asked to review the generated medication regimen and provide the following information: (1) itemized "continue" or "discontinue" recommendations for each

medication in the recommended regimen with brief rationale, (2) reasons for discontinuation including medication error, therapy optimization, lack of indication, or other, (3) evaluation for the presence of life-threatening recommendations made by the LLM, (4) perceived agreement with the medication regimen on a 1-5 Likert Scale with 1 being strongly disagree and 5 being strongly agree, and (5) any qualitative comments on perception of the medication regimens.

Data Analysis: Descriptive analyses were conducted to characterize rate of continuation of each medication recommended by the LLM, reasons for medication discontinuation, and presence of life-threatening recommendations. Data are reported as mean and standard deviation.

Results

The clinician panel consisted of 7 critical care pharmacists (3 males, 4 females) with board certification in critical care pharmacotherapy. Demographic characteristics are provided in Supplemental Content – Table 1.

The rate of continuation was 59.4% (17.4) for GPT-3.5, 67.5 (17.2) for GPT-4, 56.4 (17.8) LLaMa-2-70b, and 55.6 (15.2) for Claude-2. Percent continuation was significantly different between AI models F = 5.06, p = 0.002. Upon post-hoc pairwise analysis, GPT-4 had a significantly higher rate of continuation than LLaMa-2-70b or Claude-2.

For the medications that were recommended to be discontinued, a total of 16 medication errors were reported for GPT-3.5, 11 errors for GPT-4, 27 errors for LLaMa-2-70b, and 30 errors for Claude-2. Therapy optimization was recommended for 130 for GPT-3.5, 130 for GPT-4, 147 LLaMa-2-70b, and 130 for Claude-2. Lack of indication was listed for 58 in GPT-3.5, 65 for GPT-4, 93 for LLaMa-2-70b, and 60 forClaude-2.

The presence of life-threatening recommendations made by the LLM occurred at a rate of 38.8% on GPT-3, 12.2% in GPT-4, 22.4% in LLaMa-2-70b, and 46.9% in Claude-2. Upon pairwise analysis GPT-4 had significantly less life-threatening errors than GPT-3.5 or Claude-2. All other comparisons were non-significantly different.

The median perceived agreement with the medication regimen on a 1-5 Likert Scale was 2 (1-3) for GPT-3.5, 2 (2-3) for GPT-4, 2 (1-3) for LLaMa-2-70b, and 2 (1-3) for Claude-2. The distributions of the Likert scores were significantly different between groups, $X^2 = 15.93$, p 0.001. Post-hoc pairwise comparison revealed GPT-4 was ranked significantly higher than LLaMa-2-70b or Claude-2 while other comparisons were not different.

A A	0 1	
AI Model	Life-threatening error	p-value
GPT-3	$19(38.8)^{a}$	
GPT-4	6 (12.2) ^{b, c}	0.0007
LlaMa-2-70b	11 (22.4) ^{a, c}	0.0007
Claude-2	23 (46.9) ^a	

Pooled proportion of life-threatening errors per AI model

a, b, c: rows with different letter superscripts are significantly different from each other upon pairwise comparison using Chi-squared test with Bonferroni correction for multiple comparisons.

Tooled Tate of continuation per AT model						
AI Model	Average rate of continuation	p-value				
GPT-3	59.4% (17.4) ^{a, c}					
GPT-4	67.5 (17.2) ^a	0.002				
LlaMa-2-70b	56.4 (17.8) ^{b, c}	0.002				
Claude-2	55.6 (15.2) ^{b, c}					

Pooled rate of continuation per AI model

a, b, c: rows with different letter superscripts are significantly different from each other upon pairwise comparison using Tukey's test with Bonferroni correction for multiple comparisons.

AI Model	Score, median (IQR)	Score, mean (standard deviation)*
GPT-3	$2(2-3)^{a}$	2.2 (1.0)
GPT-4	$2(2-3)^{b}$	2.6 (1.1)
LlaMa-2-70b	$2(1-3)^{a}$	1.9 (0.9)
Claude-2	$2(1-3)^{a}$	1.8 (0.9)

Pooled median and mean Likert scores per AI model

a, b: rows with different letter superscripts are significantly different from each other upon pairwise comparison using Dunn's test with Bonferroni correction for multiple comparisons. * Mean and standard deviation reported for descriptive purposed only and were not compared

using inferential statistics.

Discussion

In the first evaluation of LLMs ability to provide comprehensive medication management on complex, critically ill patient medication regimens, a high rate of life-threatening clinical pharmacotherapy recommendations likely to cause life-threatening errors were provided. At present, the findings from this study warrant caution when using LLMs as a clinical support tool.

A "medication error" is a broad term that can range from minor oversights with little potential to cause patient harm (e.g., therapy duplication from two orders of a bowel regimen) to critical mistakes that can result in significant adverse outcomes (e.g., only providing gram-positive antibiotic coverage in a patient with gram-negative bacteremia). To deconstruct the medication recommendations provided by the LLMs, our study categorized the reasons why clinical experts discontinued medications recommended by the LLMs and found a high rate of life-threatening pharmacotherapy recommendations by LLMs (15-55.3%). In a patient experiencing elevated intracranial pressures, one LLM recommended administering a 250 mL bolus of 23% hypertonic saline, a medication that is typically administered as a 30 mL bolus when treating neurologic emergencies.

Our methodology was structured to maximize the LLMs' understanding and application of clinical knowledge in the formulation of medication plans.¹⁰ By employing reasoning engines (i.e., chain of thought) and zero-shot training via emphasizing the importance of the ground truth formatting, we aimed to enhance the models' ability to process and apply complex medical information. This was further supported by the comparative analysis of the responses across different LLMs, providing insights into their respective capabilities and limitations in medical decision-making tasks. Throughout the study, the effectiveness of the two-step prompting process and the chain-of-thought method was assessed based on the accuracy and clinical relevance of the medication plans generated by the LLMs. The structured approach and comparative analysis offer valuable contributions to the ongoing exploration of LLMs' potential in healthcare applications, particularly in the context of medication management and treatment planning. Notably, the refinement of chain-of-thought (or related concepts like tree-of-thought and graph-of-thought) in combination zero or few shot learning are rapidly implementable methods even as new medication knowledge and LLM technology progress, which are helpful for keeping such technology up to date. Indeed, this strategy is particularly helpful in healthcare where labeled data (i.e., a dataset with annotated 'correct' answers) are scarce and because the prompts support in-context learning, which can help sidestep the exhaustive fine-tuning process.^{11, 12} Reasoning engines break up problems into steps from which logical inferences can be made. Reasoning engines are useful because they reduce hallucinations and support assessment for logical or training gap.¹³⁹ This structured approach to reasoning can be particularly beneficial in capturing the nuances of clinical decision-making.

This evaluation is the first to evaluate an LLM's ability to manage complex medication regimens, with strengths including the establishment of a clinically valid ground truth and a diverse clinician panel. However, some limitations exist including that the LLM was not provided all information generally available in the electronic health record and a small sample size.

Conclusion

The ability for GPT-4 to provide CMM remains an ongoing area of investigation.

ChatGPT	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Average
								User
								rate
AC	6/11	9/12	12/18	5/10	4/7	13/14	15/17	3.00
	(54.5%)	(75%)	(66.7%)	(50%)	(57.1%)	(92.9%)	(88.2%)	
AM	6/11	6/12	11/18	4/9	4/7	12/14	12/17	1.71
	(54.5%)	(50%)	(61.1%)	(44.4%)	(57.1%)	(85.7%)	(70.6%)	
BM	4/11	5/12	14/18	5/9	4/7	14/14	11/17	2.86
	(36.4%)	(41.7%)	(77.8%)	(55.6%)	(57.1%)	(100%)	(64.7%)	
EB	5/10	8/12	14/18	6/9	1/7	10/14	10/17	2.71
	(50%)	(66.7%)	(77.8%)	(66.7%)	(14.3%)	(71.4%)	(58.8%)	
KK	6/11	8/12	14/18	6/9	4/7	12/14	12/17	1.71
	(55%)	(67%)	(78%)	(67%)	(57%)	(86%)	(71%)	
SS	3/11	4/12	10/18	5/9	2/7	8/14	7/17	1.57
	(27%)	(33%)	(55%)	(55%)	(28%)	(57%)	(41%)	
TH	7/11	10/12	8/18	6/9	4/7	8/14	9/17	1.86
	(64%)	(83%)	(44%)	(67%)	(57%)	(57%)	(53%)	
Average	48.7%	59.5%	62.8%	57.9%	46.9%	78.6%	63.4%	
(SD)	(12.5%)	(18.3%)	(16.5%)	(9%)	(17.9%)	(17%)	(15%)	

Table 1. ChatGPT performance on seven patient cases as rated by a clinician panel

Average (SD) over all cases: 59.7% (10.5%)

GPT4	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	User
								rate
AC	10/14	16/19	12/18		7/9	14/15		3.75*
	(71.4%)	(84.2%)	(66.7%)		(77.7%)	(93.3%)		
AM	9/14	16/19	11/18	8/14	5/9	13/15	15/17	1.86
	(64.3%)	(84.2%)	(61.1%)	(57.1%)	(55.6%)	(86.7%)	(88.2%)	
BM	8/14	14/19	14/18	7/14	6/9	15/15	13/17	3.5**
	(57.1)	(73.7%)	(77.8%)	(50%)	(66.7%)	(100%)	(76.5%)	
EB	8/14	17/19	14/18	9/14	1/9	13/15	11/17	3.57
	(57.1)	(89.5%)	(77.8%)	(64.3%)	(11.1%)	(86.7%)	(64.7%)	
KK	7/12	16/18	14/18	10/14	4/9	13/15	15/17	2.00**
	(58%)	(89%)	(78%)	(71%)	(44%)	(87%)	(88%)	
SS	9/14	12/19	9/18	8/14	2/9	11/15	9/17	1.86
	(64%)	(63%)	(50%)	(57%)	(22%)	(73%)	(53%)	
TH	11/14	16/19	9/18	8/14	5/9	9/15	11/16	2.14
	(79%)	(84%)	(50%)	(57%)	(55%)	(60%)	(69%)	
Average	64.5%	81.1%	65.9%	59.5%	47.6%	83.8%	73.2%	
(SD)	(8.1%)	(9.5%)	(12.6%)	(7.4%)	(23.8%)	(13.3%)	(13.9%)	

Table 2. GPT4 performance on seven patient cases as rated by a clinician panel

Average (SD) over all cases: 67.9% (12.6%)

1.) * = average over 4 cases

2.) ** = average over 6 cases

LLAMA2	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	User
								rate
AC	11/15	18/21	16/22		6/9	13/19		3.00***
	(73.3%)	(85.7%)	(72.7%)		(66.7%)	(68.4%)		
AM	11/15	13/22	16/21	3/15	5/9	12/19	5/10	1.86
	(73.3%)	(59.1%)	(76.2%)	(20%)	(55.6%)	(63.2%)	(50%)	
BM	6/15	11/21	16/22	7/15	5/9	13/19	4/10	3.50**
	(40%)	(52.4%)	(72.7%)	(46.7%)	(55.6%)	(68.4%)	(40%)	
EB	9/15	17/21	18/22	4/15	2/9	10/19	3/10	3.57
	(60%)	(81%)	(81.8%)	(26.7%)	(22.2%)	(52.6%)	(30%)	
KK	12/15	17/21	19/22	11/15	5/9	13/19	4/10	2.00**
	(80%)	(81%)	(86%)	(73%)	(55%)	(68%)	(40%)	
SS	8/15	9/21	13/22	5/15	3/9	10/19	2/10	1.86
	(53%)	(43%)	(59%)	(33%)	(33%)	(53%)	(20%)	
TH	10/15	15/21	13/21	10/14	5/9	9/19	5/10	2.14
	(67%)	(71%)	(62%)	(71%)	(55%)	(47%)	(50%)	
Average	63.8%	67.6%	73%	45.2%	49.2%	60.1%	38.3%	
(SD)	(13.8%)	(16.4%)	(9.9%)	(22.8%)	(15.5%)	(9%)	(11.7%)	

-10 m -10	T AGGAG OG POTAA DV O AUDIAIOD DOI	101
Table 5. LLAWA2 performance on seven patient	i cases as rated by a chincian par	Iei

Average (SD) over all cases: 56.8% (12.7%)

3.) *** = average over 3 cases

Claude	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	User
								rate
AC	8/11	9/15	8/15		6/8	8/12		2.67***
	(72.7%)	(60%)	(53.3%)		(75%)	(66.7%)		
AM	6/11	7/15	10/15	5/9	5/8	5/12	4/8	1.43
	(54.5%)	(46.7%)	(66.7%)	(55.6%)	(62.5%)	(41.7%)	(50%)	
BM	5/11	7/15	9/15	4/9	5/8	9/12	5/8	2.43
	(45.5%)	(46.7%)	(60%)	(44.4%)	(62.5%)	(75%)	(62.5%)	
EB	7/11	7/15	8/14	7/9	2/8	7/12	5/8	2.43
	(63.6%)	(46.7%)	(57.1%)	(77.8%)	(25%)	(58.3%)	(62.5%)	
KK	8/11	7/15	11/15	7/9	5/8	3/12	5/8	1.29
	(73%)	(47%)	(73%)	(78%)	(63%)	(25%)	(63%)	
SS	6/11	4/15	8/15	4/9	2/8	4/12	2/8	1.29
	(55%)	(27%)	(53%)	(44%)	(25%)	(33%)	(25%)	
TH	6/11	9/15	13/14	7/9	4/8	5/12	5/8	1.43
	(55%)	(60%)	(93%)	(78%)	(50%)	(42%)	(63%)	
Average	59.7%	47.6%	65.2%	63%	51.8%	48.8%	54.1%	
(SD)	(10.3%)	(11.2%)	(14.2%)	(16.7%)	(19.7%)	(18.3%)	(15.1%)	

Table 4. Claude performance on seven patient cases as rated by a clinician panel

Average (SD) over all cases: 55.8% (7%)

	ChatGPT	GPT4	LlaMa2	Claude
Continue individual	59.7% (10.5%)	67.9% (12.6%)	56.8% (12.7%)	55.8% (7%)
therapy, mean (SD)				
Reasons for discontinu	ation, mean (SD)			
Medication error	2.29 (1.7)	1.57 (2.51)	3.86 (4.41)	4.29 (3.77)
Therapy	20 (5.94)	19 (6.81)	22.7 (8.34)	18.57 (6.05)
optimization				
Lack of indication	8.29 (4.50)	9.29 (5.09)	12.71 (7.74)	8.57 (4.43)
Other	1.43 (0.96)	0.14 (0.38)	1.71 (2.87)	1.86 (1.95)
Number of life-	19/46 (41.3%)	6/40 (15%)	11/38 (28.9%)	21/38 (55.3%)
threatening				
recommendations,				
mean (SD)				
Perceived agreement	2.20	2.67	2.03	1.85
with regimen				

Table 5. Agreement of clinician panel and LLMs with therapy recommendations

Supplemental Digital Content

Table 1. Demographic features of clinician panel

	Gender	Years in	Board	Post-	Geographic
		practice	certification in	graduate	region
			critical care	residency	
			pharmacotherapy	training in	
				critical care	
AC	Μ	2	Yes	Yes	Southeast
AM	F	1	Yes	Yes	Midwest
BM	М	11	Yes	Yes	Northwestern
EB	F	12	Yes	Yes	Midwest
KK	F	3	Yes	Yes	Southeast
SS	F	7	Yes	Yes	Southeast
TH	М	4	Yes	Yes	Southeast
l	I	I	Į	I	

References

- 1. Chowdhery A, Narang S, Devlin J, et al. PaLM: Scaling Language Modeling with Pathways. Published online October 5, 2022. doi:10.48550/arXiv.2204.02311
- 2. Liang P, Bommasani R, Lee T, et al. Holistic Evaluation of Language Models. Published online October 1, 2023. doi:10.48550/arXiv.2211.09110
- 3. Yang J, Jin H, Tang R, et al. Harnessing the Power of LLMs in Practice: A Survey on ChatGPT and Beyond. Published online April 27, 2023. doi:10.48550/arXiv.2304.13712
- Sallam M. ChatGPT Utility in Healthcare Education, Research, and Practice: Systematic Review on the Promising Perspectives and Valid Concerns. *Healthc Basel Switz*. 2023;11(6):887. doi:10.3390/healthcare11060887
- Bužančić I, Belec D, Držaić M, et al. Clinical decision making in benzodiazepine deprescribing by HealthCare Providers vs AI-assisted approach. *Br J Clin Pharmacol*. Published online November 10, 2023. doi:10.1111/bcp.15963
- Hsu HY, Hsu KC, Hou SY, Wu CL, Hsieh YW, Cheng YD. Examining Real-World Medication Consultations and Drug-Herb Interactions: ChatGPT Performance Evaluation. *JMIR Med Educ*. 2023;9:e48433. doi:10.2196/48433
- 7. Kunitsu Y. The Potential of GPT-4 as a Support Tool for Pharmacists: Analytical Study Using the Japanese National Examination for Pharmacists. *JMIR Med Educ*. 2023;9:e48452. doi:10.2196/48452
- 8. Wei J, Wang X, Schuurmans D, et al. Chain-of-Thought Prompting Elicits Reasoning in Large Language Models. Published online January 10, 2023. doi:10.48550/arXiv.2201.11903
- 9. Rae JW, Borgeaud S, Cai T, et al. Scaling Language Models: Methods, Analysis & Insights from Training Gopher. Published online January 21, 2022. doi:10.48550/arXiv.2112.11446
- 10. Naveed H, Khan AU, Qiu S, et al. A Comprehensive Overview of Large Language Models. Published online November 2, 2023. doi:10.48550/arXiv.2307.06435
- 11. Kojima T, Gu SS, Reid M, Matsuo Y, Iwasawa Y. Large Language Models are Zero-Shot Reasoners. Published online January 29, 2023. doi:10.48550/arXiv.2205.11916

Supplemental Digital Content

#1 Patient Case

H&P Note: This is an 85-year-old male history of spinal cord injury gastroesophageal reflux disease nonverbal who presents today for vomiting abdominal pain. His urinalysis is positive for blood, nitrates, moderate leukocyte esterase, to numerous to count white blood cells, and 4+ bacteria, although patient does have a chronic Foley catheter with unknown timing of last exchange. Urology was consulted and exchanged foley in the emergency department. CT showed large, formed stool ball in the rectum large stool burden in the distal sigmoid colon suggestive of severe constipation as well as some thickening suggestive of stercoral colitis. Surgery was consulted and attempted disimpaction at bedside but were unsuccessful. Vitals were notable for significant hypotension requiring initiation of norepinephrine after 2 liters of fluids. He was given a dose of vancomycin, ceftriaxone, and metronidazole and admitted to the medical intensive care unit for further workup and management. The patient has not had a bowel movement in several weeks, is cachectic appearing, and is refusing enteral feeding.

Vital Signs

MAP: 56 - 71 SBP: 97 - 148 HR: 64 - 103 RR: 16 - 28 Temperature: 34.4-38.1 Non-intubated, saturating from 92 to 100% on room air

Laboratory Values:

Sodium: 135 Potassium: 3.9-4.7 (decreasing) Chloride: 104-109 CO2: 13-14 Glucose: 55 - 106 Blood urea nitrogen: 42-46 Creatinine: 2.33 - 1.93 (decreasing) Magnesium: 1.7 Phosphorous: 5.5 - 3.6 (decreasing) Calcium: 7.8 - 8.1

Other relevant labs WBC: 12.1 – 24.9 (increasing) Hb: 9.2 Plt: 302 Albumin: 2.7 MRSA/MSSA PCR: positive

Blood cultures and urine cultures negative to date (drawn 5/6, 5/7) Vancomycin level: 8 mcg/mL

Home Medication List:

Aspirin 81 mg daily Pantoprazole 40 mg daily Tizanidine 2 mg Q8H

Current Medications:

Acetaminophen 650 mg q4h PRN pain 1-3 Ceftriaxone 1000 mg IV q24 Dextrose 5% 0.9% NaCl 50 mL/hr D50 25 mL PRN D50 50 mL PRN Glucagon 1 mg PRN Glucose tab 16 gm PO PRN Glucose 40% gel 1 application PRN Heparin 5000 unit q8h Hydrocortisone 50 mg IV q6h Levothyroxine 75 mcg daily Magnesium hydroxide 30 mL PO BID PRN constipation Metronidazole 500 mg IV q8h Multivitamin with minerals 1 tab PO Daily Norepinephrine continuous infusion 0.09 mcg/kg/hr (maximum was yesterday at 0.3 mcg/kg/hr) Pantoprazole 40 mg PO BID Polvethylene glycol 17 gm PO Oday Polyethylene glycol 17 gm PO BID Senna 8.6 mg OHS Vancomycin PRN dosing per pharmacy Vancomycin 1250 mg IV x 1

Ground Truth:

Acetaminophen 650 mg q4h PRN pain 1-3 Piperacillin-tazobactam 4.5 gm IV Q8H Dextrose 5% 0.9% NaCl 50 mL/hr D50 25 mL PRN D50 50 mL PRN Glucagon 1 mg PRN Glucose tab 16 gm PO PRN Glucose 40% gel 1 application PRN Heparin 5000 unit q8h Hydrocortisone 50 mg IV q6h Levothyroxine 75 mcg daily Multivitamin with minerals 1 tab PO Daily Norepinephrine continuous infusion 0.09 mcg/kg/hr (maximum was yesterday at 0.3 mcg/kg/hr) Pantoprazole 40 mg PO BID Polyethylene glycol 17 gm PO Q8H Senna 8.6 mg QHS

Commentary:

- Would consolidate vanc, metronidazole, ceftriaxone to zosyn to cover for enterococcus and other enteric pathogens.
- MRSA PCR positive but not worried about pneumonia so ok d/c'ing vancomycin if enterococcus covered with penicillin
- Consolidate two PEG orders to a Q8H order
- Patients whole reason for being here is stool ball and IAI potential- would probably escalate with more laxatives i.e. lactulose and get rid of PRNs, should be physician talking about it

#2

H&P Note: HPI, discussion of systems (no PHI, any ability to reduce abbreviations is good) This is an 85-year-old male history of spinal cord injury gastroesophageal reflux disease nonverbal who presents today for vomiting abdominal pain. His urinalysis is positive for blood, nitrates, moderate leukocyte esterase, to numerous to count white blood cells, and 4+ bacteria, although patient does have a chronic Foley catheter with unknown timing of last exchange. Urology was consulted and exchanged foley in the emergency department. CT showed large, formed stool ball in the rectum large stool burden in the distal sigmoid colon suggestive of severe constipation as well as some thickening suggestive of stercoral colitis. Surgery was consulted and attempted disimpaction at bedside but were unsuccessful. Patients caregiver reports difficulty breathing developing over the past 3 days and subjective fever. Vitals were notable for significant hypotension requiring initiation of norepinephrine after 2 liters of fluids. He was given a dose of vancomycin and metronidazole and admitted to the medical intensive care unit for further workup and management. The patient has not had a bowel movement in several weeks, is cachectic appearing, and is refusing enteral feeding.

Vital Signs (last 24 hour range or so, whatever you look at):

MAP: 40 - 68 SBP: 97 - 110 HR: 96 - 112 RR: 22 - 28 Temperature: 39.1 On 6 L nasal cannula saturating 90-95%

Laboratory Values:

Sodium: 135 Potassium: 3.9-4.7 (decreasing) Chloride: 104-109 CO2: 10 Glucose: 55 - 106 Blood urea nitrogen: 42-46 Creatinine: 2.4 (decreasing) Magnesium: 1.7 Phosphorous: 3.6 – 5.5 (increasing) Calcium: 7.8 – 8.1

Other relevant labs WBC: 12.1 – 24.9 (increasing) Hb: 9.2 Plt: 302 Albumin: 2.7 MRSA/MSSA PCR: positive

Blood cultures and urine cultures negative to date (drawn 5/6, 5/7) Sputum culture: non-lactose fermenting gram negative rods

Vancomycin level: 8 mcg/mL

Home Medication List (from HPI is good):

Aspirin 81 mg daily Pantoprazole 40 mg PO BID Tizanidine 2 mg Q8H

Current Medications:

Acetaminophen 650 mg q4h PRN pain 1-3 Ceftriaxone 1000 mg IV q24 Dextrose 5% 0.9% NaCl 50 mL/hr D50 25 mL PRN D50 50 mL PRN Glucagon 1 mg PRN Glucose tab 16 gm PO PRN Glucose tab 16 gm PO PRN Glucose 40% gel 1 application PRN Levothyroxine 75 mcg daily Magnesium hydroxide 30 mL PO BID PRN constipation Multivitamin with minerals 1 tab PO Daily Norepinephrine continuous infusion 0.26 mcg/kg/hr Polyethylene glycol 17 gm PO Qday Polyethylene glycol 17 gm PO BID Senna 8.6 mg QHS

Ground Truth:

Acetaminophen 650 mg q4h PRN pain 1-3 Piperacillin-tazobactam 4.5 gm IV O8H Dextrose 5% 0.9% NaCl 50 mL/hr D50 25 mL PRN D50 50 mL PRN Glucagon 1 mg PRN Glucose tab 16 gm PO PRN Glucose 40% gel 1 application PRN Heparin 5000 unit q8h Hydrocortisone 50 mg IV q6h Levothyroxine 75 mcg daily Multivitamin with minerals 1 tab PO Daily Norepinephrine continuous infusion 0.26 Vasopressin 2.5 unit/hr Pantoprazole 40 mg PO BID Polyethylene glycol 17 gm PO Q8H Senna 8.6 mg QHS Vancomycin pulse dose

Commentary:

Would add Zosyn for GRN NLF coverage in sputum since patient experiencing respiratory symptoms. Also covers anaerobes for IAI process Need an order for vancomycin, only received one dose in ED and not reordered / level = 8, MRSA PCR positive so reasonable to keep Consolidate two PEG orders to a Q8H order Norepinephrine 0.26 mcg/kg/min, need to add second vasopressor to minimize and add hydrocortisone shock dose Need to add DVT prophylaxis

Need to add pantoprazole 40 mg BID because home med but also technically due to shock he would qualify for GI ppx

#3

H&P Note: HPI, discussion of systems (no PHI, any ability to reduce abbreviations is good) 31 year old male with history of end stage renal disease on hemodialysis, hypertension, diabetes, syringomyelia with functional paraplegia presenting with respiratory distress. Patient was intubate in emergency department.

Vital Signs (last 24 hour range or so, whatever you look at):

MAP: 90-134 SBP: 110-155 HR: 70-82 RR: 11-20 Temperature: 35.8-37.6

Laboratory Values:

Sodium: 135 Potassium: 3.6 Chloride: 91 CO2: 30 Glucose: 272 Blood urea nitrogen: 25 Creatinine: 3.81 Magnesium: 2 Phosphorous: 3 Calcium: 9.4 BNP 2700 MRSA PCR +

If intubated, ABG + basic ventilator settings:

pH: 7.64 PaCO2: PaO2:164 HCO3: 32.5 Mode:PRVC Rate: 14 Tidal volume: 500 Pressure: 8

Other relevant elements for your decision making (ECHO vs. cultures):

Recent admission to hospital (<3 months ago, with receipt of IV antibiotics) History of klebsiella pneumo in urine RASS -3

Home Medication List (from HPI is good):

Amlodipine 10mg PO daily Aspirin 81mg daily

Calcitriol 0.5mcg PO daily Carvedilol 25mg PO BID Clotrimazole ointment BID Famotidine 20mg BID Ferrous sulfate 325mg daily Folic acid 1mg daily Hydralazine 25mg po q8h Hydrocortisone ointment bid Glargine 18 units SQ QHS lispro 10units TIDAC Loperamide 2mg PO Q6h Rosuvastatin 5mg daily Sevelamer 800mg TIDWM

Today's MAR (+relevant One Time Only/OTO meds, please include drip rates):

Amlodipine 10mg PO daily Aspirin 81mg daily Baclofen 10mg Q8H Carvedilol 12.5mg q12h Cefepime 1g q24h Chlorhexidine 15ml PO BID Famotidine 20mg daily SQ heparin 5000 unit q8h Hydralazine 50mg q8h Insulin glargine 15 units Insulin lispro 7 units q4h Sliding scale insulin Losartan 50mg daily Vancomycin pulse dosing PRN fentanyl 50mcg Dexmedetomidine 1.5mcg/kg/hr Fentanyl 3.5mcg/kg/hr Nicardipine 1mg/hr

Ground Truth:

Amlodipine 10mg PO daily Aspirin 81mg daily Folic acid 1mg daily Carvedilol 25mg q12h Cefepime 1g q24h Chlorhexidine 15ml PO BID Famotidine 20mg daily SQ heparin 5000 unit q8h Hydralazine 25mg q8h Insulin glargine 18 units Insulin lispro 10 units TIDAC Rosuvastatin 5mg daily Sliding scale insulin Losartan 50mg daily Vancomycin pulse dosing PRN fentanyl 50mcg Dexmedetomidine 1.5mcg/kg/hr Fentanyl 2mcg/kg/hr

Commentary:

D/c nicardipine – basically off already, dose too low to matter Increase insulin to home regimen – blood glucose >180 (NICE SUGAR trial) Add home rosuvastatin – good to start home meds if not contraindicated, could probably cite some statin trial here Add folic acid – good to start home meds if not contraindicated Increase carvedilol to 25mg BID and try to decrease hydralazine to home dosing – carvedilol is better for blood pressure than hydralazine (see HTN guidelines) Decrease fentanyl infusion to 2mcg/kg/min to target RASS 0 to -2 – PADIS guidelines, goal RASS 0 to -2 Dc baclofen – unclear indication

#4

H&P Note: 58 year old female presenting as a code stroke after falling out of her wheelchair and hitting her head. Stroke workup has been negative and neurology has recommended workup for metabolic encephalopathy. She has had reduced PO intake for the past 10 days after being diagnosed with a urinary tract infection and started nitrofurantoin and ciprofloxacin.

Vital Signs (last 24 hour range or so, whatever you look at):

MAP: 55-60 SBP: 94-138 HR: 79-113 RR: 16-24 Temperature: 37.1-38.7

Laboratory Values:

Sodium: 134 Potassium: 3.6 Chloride: 99 CO2: 25 Glucose: 137 Blood urea nitrogen: 16 Creatinine: 0.55 Magnesium: Phosphorous: Calcium: WBC: 13.7

Other relevant elements for your decision making (ECHO vs. cultures):

Blood cultures preliminarily identified as enterococcus faecalis Penicillin allergy – angioedema – severe

Home Medication List:

Acetaminophen 975mg PO q6h Aspirin 81mg daily Atorvastatin 40mg daily Ergocalciferol 50000 units weekly Lacosamide 50mg BID Levetiracetam 1500mg BID Melatonin 6mg QHS Multivitamin daily Oxycodone 5mg PO q4h PRN pain Sitagliptin 100mg PO daily Nitrofurantoin 100mg BID Ciprofloxacin 250mg BID Citalopram 20mg daily

Today's MAR:

Atorvastatin 40mg QPM Aspirin 81mg daily Cefepime 2g q8h IV Citalopram 20mg daily Famotidine 20mg PO BID SQ heparin 5000 unit q8h Lacosamide 100mg BID LR 1500ml bolus x 1 Levetiracetam 500mg BID Metronidazole 500mg q8h Vancomycin 1250mg q8h Norepinephrine 0.06mcg/kg/min

<u>Ground Truth:</u> Atorvastatin 40mg QPM Aspirin 81mg daily Citalopram 20mg daily Famotidine 20mg PO BID SQ heparin 5000 unit q8h Lacosamide 50mg BID LR 1500ml bolus x 1 Levetiracetam 1500mg BID Vancomycin 1250mg q8h Norepinephrine 0.06mcg/kg/min Ergocalciferol 50000 units weekly Multivitamin daily Sliding scale insulin SQ q6h

Commentary:

D/c metronidazole – does not cover enterococcus faecalis d/c cefepime – does not cover enterococcus faecalis Increase levetiracetam to home dosing – do not want patient to have a seizure Decrease lacosamide to home dosing – no reason to give higher dose if patient was previously controlled on lower dose Resume ergocalciferol – good to start home meds if not contraindicated Resume multivitamin – good to start home meds if not contraindicated Start sliding scale insulin – on sitagliptin at home Assess volume status – surviving sepsis campaign

#5

H&P Note: 47 y.o. female with opiate abuse, tobacco use, esophageal varices s/p banding (01/2023) and decompensated cirrhosis without ongoing hepatology care who presents from OSH ED with confusion/somnolence, hematemesis x 1, generalized abdominal pain, and poor PO intake for the past 3 days. Was hypotensive with MAP of 46 requiring pressor support and intubation. Transferring to UNC MICU for work-up of newly AKI and shock likely secondary to sepsis vs hypovolemic in setting of AMS, UGIB, and abdominal pain likely 2/2 decompensated cirrhosis.

Objective/Vital Signs:

Ht: 165.5 cm Wt 75 kg MAP: 46 SBP: 73 HR: 107 RR: 23 Temperature: 38.7 C

Laboratory Values:

Sodium: 125 Potassium: 5.2 Chloride: 96 CO2: 21 Glucose: 120 Blood urea nitrogen: 42 Creatinine: 3.61 Magnesium: 2.8 Phosphorous: 6.0 Calcium: 10.0 Lactate 2.1

WBC 23.4 Hgb 10.8 PLT 150

ABG + ventilator settings:

pH: 7.32 PaCO2: 40 PaO2: 94 HCO3: 20.7 Mode: Volume Control Rate: 16 Tidal volume: 450 PEEP: 5 FiO2: 60%

CXR with RLL infiltrate Lower respiratory culture growing Staph Aureus, positive MRSA Screen RASS -5

Today's MAR Norepinephrine 30 mcg/min Cefepime 2 g q8h Daptomycin 500 mg q48 h Lactated Ringer's 1000 mL x3 (given) Propofol 20 mcg/kg/min

Ground Truth:

Norepinephrine 30 mcg/min Vasopressin 0.03 units/min Hydrocortisone 50 mg q6h Cefepime 1 g q24h Vancomycin (target 15-20 mg/mL) Acetaminophen 1000 mg q8h Oxycodone 5 mg q4h PRN moderate pain Fentanyl 25 mcg q2h PRN Severe Pain

Commentary:

Hydrocortisone: The patient is still requiring two vasopressors at high doses despite adequate volume resuscitation. Guidelines and literature would support addition of stress dose steroids Vasopressin: Standard of care is addition of vasopressin to norepinephrine for catecholamine-sparing effects

Cefepime: Dose reduction to 1 g q24h with an estimated CrCL of ~20 mL/min Vancomycin: no risk factor for VRE; Given + MRSA screen and growth of Staph aureus from lower respiratory culture, MRSA pneumonia coverage is indicated. Given that daptomycin is inactivated by pulmonary surfactants, recommend switching to vancomycin APAP: Scheduled APAP for pain control

#6

This person was a 50 year old male presenting as a level 1 trauma after a motorcycle collision in which he was the unhelmeted driver that reportedly struck a tree and a stop sign. He had a decreased glascow coma scale on scene and upon arrival to emergency department showed a glascow coma scale of 6. Unable to obtain any additional history from patient. Patient intubated in the emergency department for airway protection. Of note, he has a history of motor vehicle collision yesterday and motorcycle collision in 2008 as well. At that time no significant past medical history was noted. Imaging significant for subdural hematoma, subarachnoid hemmrohage, intraparenchymal hemorrhage, bilateral temporal bone fractures, right Cervical 7 transverse process fracture, right 2nd/3rd rib fracture, right upper lung and right middle lung contusions, trace right pneumothorax, right LeFort III pattern fracture, right frontal bone fracture, dissections of the right common carotid and left internal carotid arteries. Patient admitted to trauma intensive care unit for every 1 hour neurologic checks and mechanical ventilation. Extraventricular drain was placed by neurosurgery and facial lacerations were repaired by oral maxillofacial surgery.

Interval: Night team reported patient had a bloody drainage from his nose. Ears nose and throat doctors were engaged to assess patients continued bloody nose. Intracranial pressures ranged from 12-40 mmHg. Patient spiked intracranial pressures after a intravenous fentanyl push. Patient self corrects intracranial pressures within a few minutes. 23% hypertonic saline was ordered and on standby. Systolic blood pressures have been 130-180 mmHg. Patient responds well to labetalol.

Vital Signs:

MAP: 78 – 101 SBP: 134- 180 HR: 57 – 82 RR: 16 (set on vent) 21 actual Temperature: 37.9 – 38.3 deg C

Laboratory Values:

Sodium: 141 Potassium: 4.1 Chloride: 107 CO2: 24 Glucose: 159 Blood urea nitrogen: 28 Creatinine: 0.57 Magnesium: 2 Phosphorous: 3.5 Calcium: 8.4

If intubated, ABG + basic ventilator settings:

pH: 7.47 PaCO2: 36.1

PaO2:93 HCO3: 26.2 Mode: PRVC Rate: Set 14, actual 21 Tidal volume: 450 Pressure: peak inspiratory pressure 31, mean airway 16

Other relevant elements for your decision making (ECHO vs. cultures):

From brocheoalveolar lavage 4 days prior Colony count of >100,000 CFU/mL Serratia marcescens sensitive to cefepime and sensitive to ceftriaxone and resistant to cefazolin Colony count of >100,000 CFU/mL Staphylococcus aureus methicillin-susceptible

Chest x-ray: Demonstrates improvement in aeration.

Intracranial pressures have range from 4 to 32 mmHg with values over 20 occurring for only a few minutes then self-resolving to values < 20 mmHg.

Home Medication List

Ultracet, 1 tab, PO, Q4HR, 1 refills

Medication Regimen:

acetaminophen oral suspension 975 mg by mouth every 6 hours Aspirin chewable 81 mg by mouth every day Bisacodyl rectal suppository per rectum every 48 hours Cefepime 2 g intravenously every 8 hours Chlorhexidine topical 15 mL buccal every 12 hours Docusate 100 mg oral liquid by mouth twice daily Enoxaparin 40 g subcutaneously every 12 hours Famotidine 20 mg tablet by mouth every 12 hours Methocarbamol 500 mg tablet by mouth every 8 hours Saline flush for central line 20 mL injection every 12 hours Senna 8.6 mg by mouth twice daily Sodium chloride 23.4 % 120 milliequivalents / 30 mL intravenously once Fentanyl 50 micrograms administered IV once as part of a as needed medication Hydralazine 10 mg administered IV once as part of a as needed medication Fentanyl infusion 1.5 mcg/kg/hr (4.94 ml/hr) Midazolam infusion 8.5 mg/hr (8.5 ml/hr) Sodium chloride 0.9% infusion 100 ml/hour Propofol infusion 40 mcg/kg/min 15.82 ml/hour **Ground Truth:**

Discontinue cefepime and start ceftriaxone as ceftriaxone covers both Serratia marcescens and Staphylococcus aureus methicillin-susceptible. Ceftriaxone is more narrow spectrum than

cefepime and therefore does not need to be used in the absence of a resistant bacteria in this circumstance. Also I would decrease sedation as intracranial pressures have been stable and the patient can continue to wean his high dose midazolam infusion as it has been on the same rate for 24 hours with minimal intracranial pressure elevations.

A- Tell me what changes you'd make (e.g., switch from cefepime to ceftriaxone b/c xyz)

B- Write out what new MAR would look like that is good.

acetaminophen oral suspension 975 mg by mouth every 6 hours Aspirin chewable 81 mg by mouth every day Bisacodyl rectal suppository per rectum every 48 hours Ceftriaxone 2 g intravenously every 24 hours Chlorhexidine topical 15 mL buccal every 12 hours Docusate 100 mg oral liquid by mouth twice daily Enoxaparin 40 g subcutaneously every 12 hours Famotidine 20 mg tablet by mouth every 12 hours Methocarbamol 500 mg tablet by mouth every 8 hours Saline flush for central line 20 mL injection every 12 hours Senna 8.6 mg by mouth twice daily Sodium chloride 23.4 % 120 milliequivalents / 30 mL intravenously once Fentanyl 50 micrograms administered IV once as part of a as needed medication Hydralazine 10 mg administered IV once as part of a as needed medication

Drips:

Fentanyl infusion 1.5 mcg/kg/hr (4.94 ml/hr) Midazolam infusion 7.5 mg/hr (7.5 ml/hr) Sodium chloride 0.9% infusion 100 ml/hour Propofol infusion 40 mcg/kg/min 15.82 ml/hour

C- Write out a MAR that you think is "bad" for this patient (make some changes that are bad and highlight)

Cefazolin 2 g intravenously every 2 hours acetaminophen oral suspension 975 mg by mouth every 6 hours Aspirin chewable 81 mg by mouth every day Bisacodyl rectal suppository per rectum every 48 hours Chlorhexidine topical 15 mL buccal every 12 hours Docusate 100 mg oral liquid by mouth twice daily Enoxaparin 40 g subcutaneously every 12 hours Famotidine 20 mg tablet by mouth every 12 hours Methocarbamol 500 mg tablet by mouth every 8 hours Saline flush for central line 20 mL injection every 12 hours Senna 8.6 mg by mouth twice daily Sodium chloride 23.4 % 120 milliequivalents / 30 mL intravenously once Fentanyl 50 micrograms administered IV once as part of a as needed medication

Hydralazine 10 mg administered IV once as part of a as needed medication

Drips:

Fentanyl infusion 1.5 mcg/kg/hr (4.94 ml/hr) Midazolam infusion 20 mg/hr (20 ml/hr) Sodium chloride 0.9% infusion 400 ml/hour Propofol infusion 10 mcg/kg/min 3.96 ml/hour

#7

This person was a 50 year old male presenting as a level 1 trauma after a motorcycle collision in which he was the unhelmeted driver that reportedly struck a tree and a stop sign. He had a decreased glascow coma scale on scene and upon arrival to emergency department showed a glascow coma scale of 6. Unable to obtain any additional history from patient. Patient intubated in the emergency department for airway protection. Of note, he has a history of motor vehicle collision yesterday and motorcycle collision in 2008 as well. At that time no significant past medical history was noted. Imaging significant for subdural hematoma, subarachnoid hemmrohage, intraparenchymal hemorrhage, bilateral temporal bone fractures, right Cervical 7 transverse process fracture, right 2nd/3rd rib fracture, right upper lung and right middle lung contusions, trace right pneumothorax, right LeFort III pattern fracture, right frontal bone fracture, dissections of the right common carotid and left internal carotid arteries. Patient admitted to trauma intensive care unit for every 1 hour neurologic checks and mechanical ventilation. Extraventricular drain was placed by neurosurgery and facial lacerations were repaired by oral maxillofacial surgery.

Interval: Night team reported patient had a bloody drainage from his nose. Ears nose and throat doctors were engaged to assess patients continued bloody nose. Intracranial pressures ranged from 12-40 mmHg. Patient spiked intracranial pressures after a intravenous fentanyl push. Patient self corrects intracranial pressures within a few minutes. 23% hypertonic saline was ordered and on standby. Systolic blood pressures have been 130-180 mmHg. Patient responds well to labetalol.

Vital Signs:

MAP: 78 – 101 SBP: 134- 180 HR: 57 – 82 RR: 16 (set on vent) 21 actual Temperature: 37.9 – 38.3 deg C

Laboratory Values:

Sodium: 141 Potassium: 4.1 Chloride: 107 CO2: 24 Glucose: 159 Blood urea nitrogen: 28 Creatinine: 0.57 Magnesium: 2 Phosphorous: 3.5 Calcium: 8.4

If intubated, ABG + basic ventilator settings: pH: 7.47

PaCO2: 36.1 PaO2:93 HCO3: 26.2 Mode: PRVC Rate: Set 14, actual 21 Tidal volume: 450 Pressure: peak inspiratory pressure 31, mean airway 16

Other relevant elements for your decision making (ECHO vs. cultures):

From brocheoalveolar lavage 4 days prior Colony count of >100,000 CFU/mL Serratia marcescens sensitive to cefepime and sensitive to ceftriaxone and resistant to cefazolin Colony count of >100,000 CFU/mL Staphylococcus aureus methicillin-susceptible

Chest x-ray: Demonstrates improvement in aeration.

Intracranial pressures have range from 4 to 32 mmHg with values over 20 occurring for only a few minutes then self-resolving to values < 20 mmHg.

Home Medication List

Ultracet, 1 tab, PO, Q4HR, 1 refills

Medication Regimen:

Cefazolin 1 g intravenously every 24 hours acetaminophen oral suspension 975 mg by mouth every 6 hours Aspirin chewable 81 mg by mouth every day Bisacodyl rectal suppository per rectum every 48 hours Chlorhexidine topical 15 mL buccal every 12 hours Docusate 100 mg oral liquid by mouth twice daily Enoxaparin 40 g subcutaneously every 12 hours Famotidine 20 mg tablet by mouth every 12 hours Methocarbamol 500 mg tablet by mouth every 8 hours Saline flush for central line 20 mL injection every 12 hours Senna 8.6 mg by mouth twice daily Sodium chloride 23.4 % 120 milliequivalents / 30 mL intravenously once Fentanyl 50 micrograms administered IV once as part of a as needed medication Hydralazine 10 mg administered IV once as part of a as needed medication

Drips: Fentanyl infusion 1.5 mcg/kg/hr (4.94 ml/hr) Midazolam infusion 20 mg/hr (20 ml/hr) Sodium chloride 0.9% infusion 400 ml/hour Propofol infusion 10 mcg/kg/min 3.96 ml/hour

Ground Truth:

Discontinue cefepime and start ceftriaxone as ceftriaxone covers both Serratia marcescens and Staphylococcus aureus methicillin-susceptible. Ceftriaxone is more narrow spectrum than cefepime and therefore does not need to be used in the absence of a resistant bacteria in this circumstance. Also I would decrease sedation as intracranial pressures have been stable and the patient can continue to wean his high dose midazolam infusion as it has been on the same rate for 24 hours with minimal intracranial pressure elevations.

acetaminophen oral suspension 975 mg by mouth every 6 hours Aspirin chewable 81 mg by mouth every day Bisacodyl rectal suppository per rectum every 48 hours Ceftriaxone 2 g intravenously every 24 hours Chlorhexidine topical 15 mL buccal every 12 hours Docusate 100 mg oral liquid by mouth twice daily Enoxaparin 40 g subcutaneously every 12 hours Famotidine 20 mg tablet by mouth every 12 hours Methocarbamol 500 mg tablet by mouth every 8 hours Saline flush for central line 20 mL injection every 12 hours Senna 8.6 mg by mouth twice daily Sodium chloride 23.4 % 120 milliequivalents / 30 mL intravenously once Fentanyl 50 micrograms administered IV once as part of a as needed medication Hydralazine 10 mg administered IV once as part of a as needed medication Fentanyl infusion 1.5 mcg/kg/hr (4.94 ml/hr) Midazolam infusion 7.5 mg/hr (7.5 ml/hr) Sodium chloride 0.9% infusion 100 ml/hour Propofol infusion 40 mcg/kg/min 15.82 ml/hour

1. Tenner ZM, Cottone MC, Chavez MR. Harnessing the open access version of ChatGPT for enhanced clinical opinions. PLOS Digit Health 2024;2:e0000355.

2. Alexander V. Eriksen MD, Sören Möller, M.Sc., Ph.D., Jesper Ryg, M.D., Ph.D. Use of GPT-4 to Diagnose Complex Clinical Cases. NEJM AI 2023;1(1) DOI: 101056/AIp23000312023.

3. Kanjee Z, Crowe B, Rodman A. Accuracy of a Generative Artificial Intelligence Model in a Complex Diagnostic Challenge. JAMA 2023;1:78-80.

4. ASHP. Comprehensive medication management, Available from https://www.ashp.org/advocacy-and-issues/key-issues/other-issues/comp

https://www.ashp.org/advocacy-and-issues/key-issues/other-issues/comprehensivemedication-

management?loginreturnUrl=SSOCheckOnly#:~:text=Definition%20of%20CMM%3A%20The%20 standard,effective%20for%20the%20medical%20condition. Accessed 4/15/24,

5. Pharmacy. ACoC. **Comprehensive Medication Management in Team-Based Care.** . <u>https://wwwaccpcom/docs/positions/misc/CMM</u> 20Briefpdf Accessed July 2018 2016.

6. CDC. Available from https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm. Accessed 8/19/23,

7. Tariq RA VR, Sinha A, et al. . Medication Dispensing Errors and Prevention. [Updated 2023 May 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <u>https://www.ncbi.nlm.nih.gov/books/NBK519065/</u>.

8. Ayers JW, Desai N, Smith DM. Regulate Artificial Intelligence in Health Care by Prioritizing Patient Outcomes. JAMA 2024;8:639-40.

9. Holmes J, Liu Z, Zhang L, et al. Evaluating Large Language Models on a Highly-specialized Topic, Radiation Oncology Physics. arXiv 2023.

10. Lin Zhao LZ, Zihao Wu, Yuzhong Chen, Haixing Dai, Xiaowei Yu, Zhengliang Liu, Tuo Zhang, Xintao Hu, Xi Jiang, Xiang Li, Dajiang Zhu, Dinggang Shen, Tianming Liu. . When Brain-inspired Al Meets AGI. <u>https://arxivorg/abs/230315935</u> Accepted by Meta-Radiology 2023.

11. Ma C, Wu Z, Wang J, et al. ImpressionGPT: An Iterative Optimizing Framework for Radiology Report Summarization with ChatGPT. arXiv 2023.

12. Guan Z, Wu Z, Liu Z, et al. CohortGPT: An Enhanced GPT for Participant Recruitment in Clinical Study. arXiv 2023.

13. Jason Wei YT, Rishi Bommasani, Colin Raffel, Barret Zoph, Sebastian Borgeaud, Dani Yogatama, Maarten Bosma, Denny Zhou, Donald Metzler, Ed H. Chi, Tatsunori Hashimoto, Oriol Vinyals, Percy Liang, Jeff Dean, William Fedus. Emergent Abilities of Large Language Models. <u>https://arxivorg/abs/220607682</u> 2022.